SPC365

Thromboembolic events in the follow up of COVID-19 patients

Session: Posters (Sessão 6 - Écran 6) - Doença Cardiovascular em Populações Especiais 2 - Covid 19
Speaker: Margarida G. Figueiredo

Congress: CPC 2022
Topic: K. Cardiovascular Disease In Special Populations
Theme: 30. Cardiovascular Disease in Special Populations
Subtheme: 30.14 Cardiovascular Disease in Special Populations - Other
Session Type: Pósters Electrónicos
FP Number: ---
Authors: Margarida g Figueiredo; Hélder Santos; Mariana Santos; Sofia b. Paula; Inês Almeida; Hugo Miranda; Samuel Almeida; João Tavares; Luís Santos; Boban Thomas; Filomena Caetano; Lurdes Almeida

<p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,sans-serif"><strong><span style="font-size:12.0pt"><span style="font-family:&quot;Times New Roman&quot;,serif">Background: </span></span></strong><span style="font-size:12.0pt"><span style="font-family:&quot;Times New Roman&quot;,serif">The severe acute respiratory syndrome in SARS-CoV-2 patients and the resultant coronavirus disease are accountable for the present pandemic status. Hospitalization patients with SARS-CoV-2 have been linked to an increased incidence of thromboembolic phenomena, particularly in critical care patients. The potential higher risk of thromboembolic events post discharged remains controversial.</span></span></span></span></p>

<p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,sans-serif"><strong><span style="font-size:12.0pt"><span style="font-family:&quot;Times New Roman&quot;,serif">Objective: </span></span></strong><span style="font-size:12.0pt"><span style="font-family:&quot;Times New Roman&quot;,serif">Review the evidence regarding the occurrence of thromboembolic events during the follow-up of </span></span><span style="font-size:12.0pt"><span style="font-family:&quot;Times New Roman&quot;,serif">SARS-CoV-2 patients.</span></span></span></span></p>

<p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,sans-serif"><strong><span style="font-size:12.0pt"><span style="font-family:&quot;Times New Roman&quot;,serif">Methods:</span></span></strong><span style="font-size:12.0pt"><span style="font-family:&quot;Times New Roman&quot;,serif"> A systemic research on MEDLINE and PUBMED with two the following terms &ldquo;COVID-19&rdquo;, &ldquo;SARS-CoV-2&rdquo;, &ldquo;thromboembolic events&rdquo;, &ldquo;embolism&rdquo;, &ldquo;thromboembolic&rdquo; and &ldquo;venous thromboembolism&rdquo;. A total of 56 results were identified. However, after excluding just abstract and repeated papers, just 41 manuscripts were analyzed. From there, just 5 papers were selected since are the only ones that described thromboembolic events after the discharge in SARS-CoV-2 patients. The 5 papers presented different and irregular follow-up periods after a discharged and reported diverse types of thromboembolic events.</span></span></span></span></p>

<p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,sans-serif"><strong><span style="font-size:12.0pt"><span style="font-family:&quot;Times New Roman&quot;,serif">Results:</span></span></strong><span style="font-size:12.0pt"><span style="font-family:&quot;Times New Roman&quot;,serif"> Five studies were selected, including a total of 3691 patients. The studies were performed with different objectives and goals, as well, did not differentiate between the clinical severity of the disease. Mean age 56.32 years old, 55.78% were male, 12.41% were admitted to intensive care units and with a median follow up of 38.63 days. The rates of thromboembolic events in SARS-CoV-2 patients after the hospitalization discharge was 3.28% (121 events in 3691 patients, reported in the 5 studies). Rates of documented acute pulmonary embolism 0.003% (10 events in 3569 patients, reported in the 3 studies), 0.001% of documented venous thromboembolism (5 events in 3495 patients, reported in the 3 studies), 0.006% of documented ischemic stroke (1 event in 163 patients, reported in the 1 study), 1.23% of other documented tromboembolic events, like a cardiac thrombus or thrombosed arteriovenous fistula, (2 events in 163 patients, reported in the 1 study). Major hemorrhagic events in SARS-CoV-2 patients during the follow up were 2.38% (6 events in 252 patients, reported in the 2 studies). Were register 2.87% deaths during the follow up period in SARS-CoV-2 patients (52 events in 1814 patients, reported in the 4 studies), nevertheless, the death etiology was unknown.</span></span></span></span></p>

<p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,sans-serif"><strong><span style="font-size:12.0pt"><span style="font-family:&quot;Times New Roman&quot;,serif">Conclusions</span></span></strong><span style="font-size:12.0pt"><span style="font-family:&quot;Times New Roman&quot;,serif">: The rates of thromboembolic events in SARS-CoV-2 patients is similar to the general population. Curiously, mortality rates in SARS-CoV-2 patients during just approximately one month of follow up was significantly higher in this population, suggesting a worst prognosis and more complications in this group. Further analysis and data are essential for a conclusion. </span></span></span></span></p>